Conferences - Results from #11000

Viewing 11001-11020 of 11872 articles

GU Cancers Symposium 2014 - Effect of prior abiraterone or enzalutamide on sipuleucel-T manufacture in PROCEED patients - Poster

GU Cancers Symposium 2014 - Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥ 80 years-old: Data from PROCEED - Poster

GU Cancers Symposium 2014 - Impact of prior radiation treatment on sipuleucel-T product parameters in PROCEED patients - Poster

GU Cancers Symposium 2014 - Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer - Poster

GU Cancers Symposium 2014 - Tumor board challenge - Session Highlights

GU Cancers Symposium 2014 - A decade in review: Prostate cancer - medical oncology - Session Highlights

GU Cancers Symposium 2014 - Prostate cancer: A decade of progress - Session Highlights

MDxHealth’s ConfirmMDx genes identify aggressive prostate cancer - data presented at the 2014 Genitourinary Cancers Symposium

GU Cancers Symposium 2014 - Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study - Session Highlights

GU Cancers Symposium 2014 - Session Highlights: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC...

GU Cancers Symposium 2014 - Session Highlights: 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study

GU Cancers Symposium 2014 - Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial - Session Highlights

GU Cancers Symposium 2014 - Session Highlights: Ten- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (SPCG VII)

GU Cancers Symposium 2014 - New developments in immunotherapy for metastatic prostate cancer - Session Highlights

GU Cancers Symposium 2014 - Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT) - Abstract

GU Cancers Symposium 2014 - Using ΝΒΝ to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa) - Abstract

GU Cancers Symposium 2014 - Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)...

GU Cancers Symposium 2014 - Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial - Abstract

Dendreon announces presentation of PROVENGE® (sipuleucel-T) data at the 2014 Genitourinary Cancer Symposium (ASCO GU)

GU Cancers Symposium 2014 - 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study - Poster

546
547
548
549
550
551
552
553
554
555